[A step towards a bioartificial liver: temporary extracorporeal replacement using isolated hepatocytes].
The mortality rate of fulminant hepatic failure is about 80%. Besides orthotopic liver transplantation, specific therapies are not currently available. Indeed, not only removal of toxins is required, by means of dialysis or hemoperfusion, but specific hepatic functions must be provided to allow spontaneous liver regeneration or as a bridge before liver transplantation. Treatment with an extracorporeal bioartificial liver is an attractive approach. This system was successfully used for the correction of the Gunn rat genetic defect which results in the lack of bilirubin conjugation. The development of this system for clinical purpose requires both a large yield of functional hepatocytes and their immunoprotection in an appropriate device. We have isolated normal porcine hepatocytes by collagenase perfusion of the liver; cells are subsequently entrapped within membrane-coated alginate beads which are inoculated in a bioreactor. Plasma from an animal undergoing fulminant hepatic failure by end-to-site portocaval shunt and whole porta hepatic tightening circulates within the bioreactor. Porcine hepatocytes express liver-specific functions at high levels, particularly secretion of plasma proteins and several enzyme activities involved in the detoxication and biotransformation of xenobiotics. In addition, hepatocytes are immunoseparated from circulating immunoglobulins. Ethical concerns are discussed in the field of physiopathology, immunopathology and public health, as a prerequisite to create departments of Cell Therapy, in the near future.